Cargando…

1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis

BACKGROUND: Rotavirus causes 215,000 deaths from severe childhood diarrhea annually. Two rotavirus vaccines – a monovalent vaccine containing a single rotavirus strain (RV1) and a pentavalent vaccine containing 5 rotavirus strains (RV5) – are used in routine immunization programs of nearly 100 count...

Descripción completa

Detalles Bibliográficos
Autores principales: Cates, Jordan, Amin, Avnika, Tate, Jacqueline, Lopman, Ben, Parashar, Umesh D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643795/
http://dx.doi.org/10.1093/ofid/ofab466.1363
_version_ 1784609935489761280
author Cates, Jordan
Amin, Avnika
Tate, Jacqueline
Lopman, Ben
Parashar, Umesh D
author_facet Cates, Jordan
Amin, Avnika
Tate, Jacqueline
Lopman, Ben
Parashar, Umesh D
author_sort Cates, Jordan
collection PubMed
description BACKGROUND: Rotavirus causes 215,000 deaths from severe childhood diarrhea annually. Two rotavirus vaccines – a monovalent vaccine containing a single rotavirus strain (RV1) and a pentavalent vaccine containing 5 rotavirus strains (RV5) – are used in routine immunization programs of nearly 100 countries. Concerns exist that rotavirus vaccines may be less effective against rotavirus strains not contained in the vaccines which could subsequently cause selective pressure and strain replacement. We estimated the vaccine effectiveness (VE) of RV1 and RV5 against vaccine (homotypic) and non-vaccine (partially and fully heterotypic) strains. METHODS: After conducting a systematic review, we meta-analyzed 31 case-control studies (N=27,293) conducted between 2006 and 2020 using a random-effect regression model. RESULTS: In high-income countries, RV1 VE was 10% lower against partially heterotypic (p-value=0.04) and fully heterotypic (p-value=0.10) compared to homotypic strains (homotypic VE: 90% [95% CI: 82, 94]; partially heterotypic VE: 79% [95% CI: 71, 85]; fully heterotypic VE: 80% [95% CI: 65, 88]; Figure 1). In middle-income countries, RV1 VE was 14 to 16% lower against partially heterotypic (p-value=0.06) and fully heterotypic (p-value=0.04) compared to homotypic strains (homotypic VE: 81% [95% CI: 69, 88]; partially heterotypic VE: 67% [95% CI: 54, 76]; fully heterotypic VE: 65% [95% CI: 52, 75]; Figure 1). Strain-specific RV5 VE differences were less pronounced (Figure 2). Limited data were available from low-income countries. Figure 1. Vaccine effectiveness by country income level and strain type, for RV1. [Image: see text] Figure 2. Vaccine effectiveness by country income level and strain type, for RV5. [Image: see text] CONCLUSION: Vaccine effectiveness of RV1 and RV5 was somewhat lower VE against non-vaccine than vaccine strains. Ongoing surveillance is crucial to continue long-term monitoring for strain replacement, particularly in low-income settings where data are limited. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-8643795
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86437952021-12-06 1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis Cates, Jordan Amin, Avnika Tate, Jacqueline Lopman, Ben Parashar, Umesh D Open Forum Infect Dis Poster Abstracts BACKGROUND: Rotavirus causes 215,000 deaths from severe childhood diarrhea annually. Two rotavirus vaccines – a monovalent vaccine containing a single rotavirus strain (RV1) and a pentavalent vaccine containing 5 rotavirus strains (RV5) – are used in routine immunization programs of nearly 100 countries. Concerns exist that rotavirus vaccines may be less effective against rotavirus strains not contained in the vaccines which could subsequently cause selective pressure and strain replacement. We estimated the vaccine effectiveness (VE) of RV1 and RV5 against vaccine (homotypic) and non-vaccine (partially and fully heterotypic) strains. METHODS: After conducting a systematic review, we meta-analyzed 31 case-control studies (N=27,293) conducted between 2006 and 2020 using a random-effect regression model. RESULTS: In high-income countries, RV1 VE was 10% lower against partially heterotypic (p-value=0.04) and fully heterotypic (p-value=0.10) compared to homotypic strains (homotypic VE: 90% [95% CI: 82, 94]; partially heterotypic VE: 79% [95% CI: 71, 85]; fully heterotypic VE: 80% [95% CI: 65, 88]; Figure 1). In middle-income countries, RV1 VE was 14 to 16% lower against partially heterotypic (p-value=0.06) and fully heterotypic (p-value=0.04) compared to homotypic strains (homotypic VE: 81% [95% CI: 69, 88]; partially heterotypic VE: 67% [95% CI: 54, 76]; fully heterotypic VE: 65% [95% CI: 52, 75]; Figure 1). Strain-specific RV5 VE differences were less pronounced (Figure 2). Limited data were available from low-income countries. Figure 1. Vaccine effectiveness by country income level and strain type, for RV1. [Image: see text] Figure 2. Vaccine effectiveness by country income level and strain type, for RV5. [Image: see text] CONCLUSION: Vaccine effectiveness of RV1 and RV5 was somewhat lower VE against non-vaccine than vaccine strains. Ongoing surveillance is crucial to continue long-term monitoring for strain replacement, particularly in low-income settings where data are limited. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2021-12-04 /pmc/articles/PMC8643795/ http://dx.doi.org/10.1093/ofid/ofab466.1363 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Cates, Jordan
Amin, Avnika
Tate, Jacqueline
Lopman, Ben
Parashar, Umesh D
1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis
title 1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis
title_full 1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis
title_fullStr 1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis
title_full_unstemmed 1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis
title_short 1170. Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review And Meta-analysis
title_sort 1170. do rotavirus strains affect vaccine effectiveness? a systematic review and meta-analysis
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643795/
http://dx.doi.org/10.1093/ofid/ofab466.1363
work_keys_str_mv AT catesjordan 1170dorotavirusstrainsaffectvaccineeffectivenessasystematicreviewandmetaanalysis
AT aminavnika 1170dorotavirusstrainsaffectvaccineeffectivenessasystematicreviewandmetaanalysis
AT tatejacqueline 1170dorotavirusstrainsaffectvaccineeffectivenessasystematicreviewandmetaanalysis
AT lopmanben 1170dorotavirusstrainsaffectvaccineeffectivenessasystematicreviewandmetaanalysis
AT parasharumeshd 1170dorotavirusstrainsaffectvaccineeffectivenessasystematicreviewandmetaanalysis